Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2024-06-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺（方灿辉）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It includes multiple attestations regarding the candidate's qualifications, independence, compliance with laws and regulations, and commitments during the tenure. There is no financial data, no discussion of financial results, no mention of annual or interim reports, earnings, or capital changes. The content is focused on the candidate's qualifications and compliance with regulatory requirements for board membership. This type of document is related to board or management information, specifically announcements or statements about changes or candidates for the board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (5722 characters) supports it being a full statement rather than a brief announcement or certification. Confidence is high due to the clear nature of the content and absence of financial or other report data.
2024-06-07 Chinese
关于召开2023年度股东大会通知的公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2023 Annual General Meeting (AGM) of 康芝药业股份有限公司. It includes information about the meeting date, location, voting procedures (both in-person and online), agenda items to be discussed and voted on, registration methods, and proxy forms. The document does not contain financial statements or detailed financial performance data but rather serves as a notice to shareholders about the upcoming AGM and the related procedural details. It explicitly mentions the 2023年度股东大会 (2023 Annual General Meeting) and provides comprehensive information for shareholders to participate and vote. Therefore, this document fits the category of AGM Information (AGM-R).
2024-06-07 Chinese
关于深圳证券交易所2023年年报问询函的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed reply announcement from Kangzhi Pharmaceutical Co., Ltd. regarding an inquiry letter from the Shenzhen Stock Exchange about the company's 2023 annual report. It discusses the company's business performance, shareholder equity pledges, financial obligations related to a buyback agreement, and detailed customer and supplier information for the years 2018 to 2023. The content is focused on addressing questions about the annual report and related financial and operational issues, including performance shortfalls and shareholder equity pledges. The document is lengthy (15,000 characters) and contains substantive financial and operational data, not merely an announcement of a report or a certification. It is not a full annual report itself but a detailed response to an inquiry about the annual report and related financial matters. This type of document fits best under the category of Regulatory Filings (RNS), as it is a regulatory disclosure responding to an exchange inquiry about the annual report, including detailed financial and operational information, but it is not the annual report itself nor a standalone audit report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-05-28 Chinese
关于参加2023年度海南辖区上市公司业绩说明会暨投资者集体接待日的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in a 2023 annual performance briefing and investor collective reception day organized by regulatory and industry bodies. It mentions that company executives will communicate with investors about the 2023 annual report, financial data, governance, and other topics. However, the document itself does not contain the annual report or detailed financial data; it is an announcement of an upcoming event related to the annual report and investor communication. The document length is short (614 characters), and it serves as a notice rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about investor relations activities.
2024-05-09 Chinese
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "康芝药业股份有限公司2023 年年度报告摘要" which translates to "Kangzhi Pharmaceutical Co., Ltd. 2023 Annual Report Summary." It contains detailed information about the company's business overview, industry environment, financial data for the year 2023, shareholder information, and important events during the reporting period. The document includes comprehensive financial figures, business descriptions, and strategic outlooks typical of an annual report. The length of the document (over 14,000 characters) and the presence of detailed financial and operational data confirm it is the report itself, not merely an announcement or summary notice. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-28 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2023年度监事会工作报告" which translates to "2023 Supervisory Board Work Report". It details the supervisory board's activities, meetings, and oversight of the company's operations, financial status, compliance, and internal controls during the 2023 fiscal year. It includes references to the review of the annual report, financial statements, audit opinions, and other governance matters. The document is a comprehensive report from the supervisory board summarizing their work and opinions on the company's governance and financial matters for the year 2023. This type of document is a management or supervisory report on the company's annual activities and oversight, which aligns with the category of Management Reports (MDA). It is not the full Annual Report (10-K), nor is it an announcement or certification. The length and content confirm it is a substantive report, not a brief announcement or regulatory filing. Therefore, the correct classification is Management Reports (MDA).
2024-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.